

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)**

Terry Davis, Ph.D.

Committees: Gastrointestinal Drugs and the Drug Safety and Risk
 Management Advisory Committees

Meeting Dates: July 31, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to Biologic License Application (BLA) 125104/33, Tysabri (Natalizumab) injection, sponsored by Biogen Idec, Inc. and Elan Pharmaceuticals, a subsidiary of Elan Corporation, plc., for the proposed indication of inducing and maintaining sustained response and remission, and eliminating corticosteroid use in patients with moderately to severely active Crohn's disease with inflammation, as evidenced by elevated C-reactive protein (CRP) level or another objective marker, and the risks (including progressive multifocal leukoencephalopathy) associated with TYSABRI (natalizumab) administration, its efficacy in the treatment of moderate to severe Crohn's disease, and proposed risk management plan(s), I am eligible to receive waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Competing Firm	Valued from \$5,001 to \$25,000
Stock	Competing Firm	Valued from \$25,001 to \$50,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/S/
Signature of SGE

6/19/2007
Date